Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer

World Journal of Surgery

Volumn 28, Issue 10, 2004, Pages 1040-1045

  Zanon, Claudio ^a   Clara, Renzo ^a   Chiappino, Isabella ^b   Bortolini, Massimiliano ^a   Cornaglia, Silvia ^a   Simone, Paolo ^a   Bruno, Francesco ^a   De Riu, Leonarda ^a   Airoldi, Mario ^a   Pedani, Fulvia ^a  

^a S Giovanni Battista Antica Sede H ^*  (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CHOLECYSTITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; HUMAN; HYDROTHORAX; HYPERTHERMIA; LUNG EMBOLISM; MORBIDITY; OVARY CANCER; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; SMALL INTESTINE PERFORATION; SURGICAL MORTALITY; SURGICAL TECHNIQUE; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 19944427160     PISSN: 03642313     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00268-004-7461-x     Document Type: Article

References (32)

1. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 1996;334:1-6
2. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl. Cancer Inst. 2000;92:669-708
3. Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol. 2003;4:277-283
4. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 1996;335:1950-1955
5. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 2001;19:1001-1007
6. Armstrong DK, Bundy BN, Baergen R, et al. Randomized phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncologic Group trial (GOG 172). Proc. Am. Soc. Clin. Oncol. 2002;21:201a, 202 (abstr 803)
7. Spratt JS, Adcocj JA, Muskovin M, et al. Clinical delivery system for peritoneal hyperthermic chemotherapy. Cancer Res. 1980;40:256-260
8. Giovanella BC, Stehlin JS, Morgan AC. Selective lethal effect of supra-normal temperatures on human neoplastic cells. Cancer Res. 1976;11:3944-3950
9. Benoit L, Duvillard C, Rat P, et al. [The effect of intra-abdominal temperature on the tissue and tumor diffusion of intraperitoneal cisplatin in a model of peritoneal carcinomatosis in rats.] Effets de la temperature intra-abdominale sur la diffusion tissulaire et tumorale du cisplatine intraperitoneal dans un modele de carcinose peritoneale chez le rat. Chirurgie 1999;124:375-379
10. Zakris EL, Dewhirst MW, Riviere JE, et al. Pharmacokinetics and toxicity of intraperitoneal cisplatin combined with regional hyperthermia. J. Clin. Oncol. 1987;5:1613-1620
11. Fujimura T, Honemura Y, Fujita H, et al. Chemohyperthermic peritoneal perfusion for peritoneal dissemination in various intra-abdominal malignancies. Int J Surg 1999;84:60-66
12. Gilly FN, Beaujard AC, Glehen O, et al. Peritonectomy combined with intraperitoneal chemohyperthermia in abdominal cancer with peritoneal carcinomatosis: a phase I-II study. Anticancer Res. 1999;19:2317-2321
13. Zanon C, Clara R, Bortolini M, et al. Chemohyperthermia for advanced abdominal malignancies: a new procedure with closed abdomen and previously performed anastomosis. Int. J. Hyperthermia 2001;17:456-464
14. Sugarbaker PH. Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal surface malignancies. In Markman M, editors, Regional Chemotherapy Totowa, NJ, Humana Press, 2000;151-166
15. Sugarbaker P. Peritonectomy procedures. Ann. Surg. 1995;221:29-42
16. Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J. Exp. Clin. Cancer Res. 1996;15:49-58
17. Elias D, Antun S, Goharin A, et al. Research on the best chemohyperthermia technique of treatment of peritoneal carcinomatosis after complete resection. Int. J. Surg. Investig. 2000;1:431-439
18. van der Burg ME, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N. Engl. J. Med. 1995;332:629-634
19. Cavaliere F, Perri P, Di Filippo F, et al. Treatment of peritoneal carcinomatosis with intent to cure. J. Surg. Oncol. 2000;74:41-44
20. Barakat RR, Sabbatici P, Bhaskaran D, et al. Intraperitoneal chemotherapy for ovarian carcinoma: results of long term follow-up. J. Clin. Oncol. 2002;20:694-698
21. Rietbroek RC, van de Vaart PJM, Haveman J, et al. Hyperthermia enhances the citotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells. Cancer Res Clin Oncol 1997;123:6-12
22. Pontiggia P, Barni S, Mathè G, et al. Lysosomal exocytosis induced by hyperthermia: a new model of cancer cell death. II. Effect on peritoneal macrophages. Biomed. Pharmacother. 1995;49:429-430
23. Panteix G, Beaujard A, Garbit F, et al. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy. Anticancer Res. 2002;22:1329-1336
24. Steller MA, Egorin MJ, Trimble EL, et al. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer. Cancer Chemother. Pharmacol. 1999;43:106-114
25. De BreeE, Rosing H, Beijnen JH, et al. Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer. Anticancer Drugs 2003;14:103-110
26. van der Vange N, Van Goethem AR, Zoetemulder FA, et al. Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. Eur. J. Surg. Oncol. 2000;26:663-668
27. der Vaart PJ, van der Vange N, Zoetmulder FA, et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur. J. Cancer 1998;34:148-154
28. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol. 1997;15:2183-2193
29. Muggia FM, Hainsworth JD, Jetters S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antittumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol. 1997;15:987-993
30. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 2001;19:3312-3322
31. Deraco M, Rossi CR, Pennacchioli E, et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. Tumori 2001;87:120-126
32. Glehen O, Mithieux F, Osinsky D, et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancer with peritoneal carcinomatosis: a phase II study. J. Clin. Oncol. 2003;21:799-806